Kees van der Graaf
Kees van der Graaf is Chief Executive Officer of Sulfateq.
Kees is a 40+ year veteran entrepreneur specialized in the pharmaceutical and biotechnology fields.
He has a background in pharmacy and was a Dutch registered pharmacist.( apotheker)
During the years with the companies the general issue has been bring Science into the market. This proven by the all healthfully companies, which have all turnover and profit on long term. Although Sulfateq is still a bleeder, but that is drug development and by this value creation on long term.
The pharmaceutical world is a business which need a vison and deep pockets for long term investments.
The profit is a to solve a medical need for mankind and has also by success a positive financial part.
Kees is the founder of several biotech companies, like
Kees next to management response for the premises ( 1000 m-2 clean room ) with complete new technologies and a specific concept now known as small foot print in mammalian production. The premises and the equipment in the building was within budget and on time.
After Bio Intermediar as a business enthusiast, Kees uses the revenues of the company first company Cityeq to invest in the next ventures. And so on.
Kees primary ambition is to develop a sustainable pharma business in the Northern Netherlands.
Kees is a 40+ year veteran entrepreneur specialized in the pharmaceutical and biotechnology fields.
He has a background in pharmacy and was a Dutch registered pharmacist.( apotheker)
During the years with the companies the general issue has been bring Science into the market. This proven by the all healthfully companies, which have all turnover and profit on long term. Although Sulfateq is still a bleeder, but that is drug development and by this value creation on long term.
The pharmaceutical world is a business which need a vison and deep pockets for long term investments.
The profit is a to solve a medical need for mankind and has also by success a positive financial part.
Kees is the founder of several biotech companies, like
- 1985 Bio-Intermediar (now ThermoFisher) producing mammalian cell culture to obtain monoclonal antibodies in fermentation, nowadays about 400 high profile FTE.
- 1994 Citeq a producer of allergen source material for allergy vaccines. Source material , like cultivating and harvesting house dust mites.
- 1998 Citeq Health products / Sanelco a whole sale and sales to consumer company in the lateral flow test. CHP. has had a 50 % market share of consumer pregnancy test from 1997 -2007, competitor Unilever and AKZO
- 2002 Angteq, A research company together with the University goal Contract research
- 2011 Sulfateq A drug development company, Developed drugs in the field of influencing Mitochondria. Application e.g. Alzheimer. The lead compound SUL238, will be in Phase 1 at Q1 in 2023.
- 2016 Tryptomera, Biobestrijding Producing predator mites for the Agriculture, This is Business to business and a webshop for consumers for biological pest control.
Kees next to management response for the premises ( 1000 m-2 clean room ) with complete new technologies and a specific concept now known as small foot print in mammalian production. The premises and the equipment in the building was within budget and on time.
After Bio Intermediar as a business enthusiast, Kees uses the revenues of the company first company Cityeq to invest in the next ventures. And so on.
Kees primary ambition is to develop a sustainable pharma business in the Northern Netherlands.
Sign in to Autumn ITAPA 2024
-
Interview: Science to the market
